Advertisement

Pharmacokinetics of Tacrolimus Ointment: Clinical Relevance

  • N. A. Undre

Abstract

Atopic dermatitis is a common inflammatory skin disease whose pathophysiology is not completely understood. Evidence now strongly points to a role for T cells and their cytokines in many phases of atopic dermatitis. Both immediate and delayed hypersensitivity seem to be involved, although how they intertwine remains a complex issue. Th2 cells appear most important in the early stages of atopic lesion development, as their cytokines (IL-4, IL-5 and IL-13) induce eosinophil proliferation and IgE production. The binding of allergen to IgE on mast cells triggers the release of mast cell mediators. When allergen-IgE complexes attach to the FCεRI and FCεRII receptors on Langerhans cells, the magnitude of the response is multiplied.

Keywords

Stratum Corneum Systemic Exposure Area Under Curve Atopic Dermatitis Patient Severe Atopic Dermatitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Alaiti S, Kang S, Fiedler VC et al. (1998) Tacrolimus (FK506) 0.3% ointment for atopic dermatitis; a phase I study in adults and children. J Am Acad Dermatol 38: 69–76PubMedCrossRefGoogle Scholar
  2. 2.
    Beysens AJ, Wijnen RMH, Beuman GH et al. (1991) Monitoring in plasma or whole blood. Transplant Proc 23: 2745–2747PubMedGoogle Scholar
  3. 3.
    Boguniewicz M, Leung DYM (1996) Management of atopic dermatitis. In: Leung DYM (ed) Atopic dermatitis: from pathogenesis to treatment. Austin, RG Landes Company, pp 185–220Google Scholar
  4. 4.
    Boguniewicz M, Leung DYM (1996) New concepts in atopic dermatitis. Compr Ther 22: 144–151PubMedGoogle Scholar
  5. 5.
    Dugard PH, Scottz RC (1984) Absorption through skin. In: Baden HP (ed) Chemotherapy of psoriasis. Oxford, Pergamon Press, pp 125–144Google Scholar
  6. 6.
    Goto T, Kino T, Hatanaka H et al. (1991) FK506: Historical perspectives. Transpl Proc 23: 2713–2717Google Scholar
  7. 7.
    Iwasaki K, Shiraga T, Nagase K et al. (1994) Isolation, identification and biological activities of oxidative metabolites of FK506 a potent immunosuppressive macrolide lactone. Drug Metab Dispos 21: 971–977Google Scholar
  8. 8.
    Iwasaki K, Shiraga T, Matsuda H et al. (1995) Further metabolism of FK506 (Tacrolimus), Identification and biological activities of metabolites oxidized at multiple sites of FK506. Drug Metab Dispos 23: 28–34PubMedGoogle Scholar
  9. 9.
    Karanam BV, Vincent SH, Lee Chiu SH (1994) FK506 metabolism in human liver microsomes: investigation of the involvement of cytochrome P450 other than CYP3A4. Drug Metab Dispos 22: 811–813PubMedGoogle Scholar
  10. 10.
    Kawashima M, Nakagawa H, Ohtsuji M et al. (1996) Tacrolimus concentrations in blood during topical treatment of atopic dermatitis (letter). Lancet 348: 1240–1241PubMedCrossRefGoogle Scholar
  11. 11.
    Machida M, Takahara S, Ishibashi M et al. (1991) Effect of temperature and hematocrit on plasma concentration of FK506. Transplant Proc 23: 2753–2754PubMedGoogle Scholar
  12. 12.
    Moeller A, Iwasaki K, Kawamura A et al. (1999) The disposition of 14 C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. Drug Metabolism and Disposition 27(6): 633–636Google Scholar
  13. 13.
    Oranje AP, Wolkerstorfer A (1999) Advances in the treatment of atopic dermatitis with special regard to children. In: Wuthrich B (ed) The Atopy Syndrome in the Third Millennium: Current Problems in Dermatology, Volume 28. Karger, Basel, pp 56–63CrossRefGoogle Scholar
  14. 14.
    Reitamo S (2002) Topical immunomodulators for therapy of atopic dermatitis. In: Bieber T, Leung D (eds) Atopic dermatitis. Marcel Dekker, New York (in press)Google Scholar
  15. 15.
    Scheuplein RJ, Blank IH (1971) Permeability of the skin. Physiological Reviews 51: 702–747PubMedGoogle Scholar
  16. 16.
    Undre N, Rubins A, Gutmane R et al. (2002) Pharmacokinetics (PK) of tacrolimus ointment in adult patients with moderate to severe atopic dermatitis. 20th World Congress of Dermatology, Paris, PosterGoogle Scholar
  17. 17.
    Undre N, Green A, Harper J et al. (2002) Tacrolimus pharmacokinetics (PK) in paediatric patients with moderate to severe atopic dermatitis (AD) after single and repeated application of tacrolimus ointment. 20th World Congress of Dermatology, Paris, PosterGoogle Scholar
  18. 18.
    Wallemacq PE, Furlan V, Moeller A et al. (1998) Pharmacokinetics of tacrolimus (FK 506) in paediatric liver transplant recipients. Eur J Drug Metabolism Pharmacokinetics 23: 367–370CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • N. A. Undre

There are no affiliations available

Personalised recommendations